PRTA
Prothena Corp. Plc · NASDAQ
- Sector Health Technology
- Industry Biotechnology
- Website rothena.com
- Employees(FY) 127
- ISIN IE00B91XRN20
Performance
+13.23%
1W
-1.45%
1M
-13.45%
3M
-36.77%
6M
-36.63%
YTD
-70.05%
1Y
Profile
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease and other related synucleinopathies; NNC6019 that completed Phase I clinical trial for the treatment of ATTR amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease, as well as TDP-43 and PRX019 for the treatment of Alzheimer's disease and other neurodegenerative diseases. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
Investment Analysis Report: PRTA
Overview
In this investment analysis report, we will delve into the financial statements of PRTA, a company operating in the Health Technology sector within the Biotechnology industry. We will analyze the company's Balance Sheets, Income Statements, and Cashflow Statements over the past three years to gain insigh...
Technical Analysis of PRTA 2024-05-03
Overview:
In analyzing the technical indicators for PRTA over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement. By examining these key indicators, we aim to offer valuable insights and predictions for the upcoming days.
Trend Analysi...
Recent News & Updates
- 2024-05-08 06:23
- 2024-05-01 16:05
- 2024-05-01 04:05
- 2024-04-25 10:01
- 2024-04-24 22:01
- 2024-04-15 16:05
- 2024-04-15 04:05
- 2024-03-28 08:00
Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback(Investor's Business Daily)
- 2024-03-26 11:21
- 2024-03-05 16:05
Prothena to Participate in Upcoming Healthcare Conferences(Business Wire)
- 2024-03-05 03:05
- 2024-03-04 16:05
- 2024-02-21 16:05
- 2024-02-17 07:45
Prothena Full Year 2023 Earnings: Beats Expectations(Simply Wall St.)
- 2024-02-16 13:33
- 2024-02-16 10:33
- 2024-02-16 00:33
- 2024-02-15 16:50
Prothena: Q4 Earnings Snapshot(Associated Press Finance)
- 2024-02-15 16:48
- 2024-02-15 16:05
- 2024-02-15 03:05
- 2024-02-08 16:05
- 2024-02-08 03:05
- 2024-02-02 02:59
- 2024-01-24 23:02
- 2024-01-10 12:06
- 2024-01-10 05:38
- 2024-01-08 08:30
- 2024-01-07 19:30
- 2023-12-21 09:01
Page 1 of 5
previousnext